WEKO3
アイテム
{"_buckets": {"deposit": "88765e1f-8987-4946-ace2-c17b97fb8edd"}, "_deposit": {"created_by": 3, "id": "20234", "owners": [3], "pid": {"revision_id": 0, "type": "depid", "value": "20234"}, "status": "published"}, "_oai": {"id": "oai:twinkle.repo.nii.ac.jp:00020234", "sets": ["2024"]}, "author_link": ["300856", "300855"], "item_10001_alternative_title_1": {"attribute_name": "別タイトル", "attribute_value_mlt": [{"subitem_alternative_title": "Cerebrovascular Disease : Recent Progress in Research and Clinical Practice (6) : Thrombolytic and Antiplatelet Therapies in Patients with Acute Ischemic Stroke"}]}, "item_10001_biblio_info_7": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2007-07", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "7", "bibliographicPageEnd": "324", "bibliographicPageStart": "319", "bibliographicVolumeNumber": "77", "bibliographic_titles": [{"bibliographic_title": "東京女子医科大学雑誌"}]}]}, "item_10001_creator_2": {"attribute_name": "著者名", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "内山, 真一郎"}], "nameIdentifiers": [{"nameIdentifier": "300855", "nameIdentifierScheme": "WEKO"}]}]}, "item_10001_date_25": {"attribute_name": "受付日付", "attribute_value_mlt": [{"subitem_date_issued_datetime": "2010-08-10", "subitem_date_issued_type": "Created"}]}, "item_10001_description_5": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Recent evidence and present consensus as well as the future direction of thrombolytic and antithrombotic therapies for the treatment of acute ischemic stroke were reviewed. Intravenous tissue plasminogen activator (t-PA; alteplase) has recently been approved in Japan to use in patients with ischemic stroke within 3 hours of onset. In order to improve the efficacy and maximize the safety, attempts have recently been made to select patients on the basis of perfusion/diffusion mismatch on magnetic resonance imaging, use of third generation t-PAs, and concomitant use of transcranial Doppler or clot retrieval device. Neither unfractionated heparin, low molecular weight heparin, or heparinoid has been proven to improve long-term outcome, while anticoagulant therapy appears to be indicated for the treatment of patients with atherothrombotic stroke, progressing stroke, basilar artery thrombosis, cardioembolic stroke at high risk of early recurrence, coagulopathy including antiphospholipid antibody and Trousseau\u0027s syndrome, and intracranial arterial dissection. The thrombin inhibitor argatroban is recommended for the treatment of atherothrombotic stroke within 48 hours of onset. Among antiplatelet agents, aspirin is recommended in patients with ischemic stroke within 48 hours of onset, although the long-term efficacy is modest. The thromboxane synthetase inhibitor ozagrel is also recommended in the Japanese guideline. A trial of the glycoprotein IIb/IIIa inhibitor abciximab has been discontinued because of safety concerns. Many clinical trials of dual antiplatelet therapy are ongoing in patients with acute ischemic stroke.", "subitem_description_type": "Abstract"}]}, "item_10001_full_name_3": {"attribute_name": "著者別名", "attribute_value_mlt": [{"nameIdentifiers": [{"nameIdentifier": "300856", "nameIdentifierScheme": "WEKO"}], "names": [{"name": "UCHIYAMA, Shinichiro"}]}]}, "item_10001_publisher_8": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "東京女子医科大学学会"}]}, "item_10001_source_id_11": {"attribute_name": "NCID", "attribute_value_mlt": [{"subitem_source_identifier": "AN00161368", "subitem_source_identifier_type": "NCID"}]}, "item_10001_source_id_9": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "0040-9022", "subitem_source_identifier_type": "ISSN"}]}, "item_10001_subject_47": {"attribute_name": "著者キーワード", "attribute_value_mlt": [{"subitem_subject": "tissue-plasminogen activator", "subitem_subject_scheme": "Other"}, {"subitem_subject": "anticoagulants", "subitem_subject_scheme": "Other"}, {"subitem_subject": "antiplatelet agents", "subitem_subject_scheme": "Other"}, {"subitem_subject": "acute ischemic stroke", "subitem_subject_scheme": "Other"}, {"subitem_subject": "guidelines", "subitem_subject_scheme": "Other"}]}, "item_10001_text_35": {"attribute_name": "著者所属", "attribute_value_mlt": [{"subitem_text_value": "東京女子医科大学医学部神経内科学"}]}, "item_10001_version_type_20": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_970fb48d4fbd8a85", "subitem_version_type": "VoR"}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2017-08-22"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "KJ00006017724.pdf", "filesize": [{"value": "645.5 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 645500.0, "url": {"label": "KJ00006017724.pdf", "url": "https://twinkle.repo.nii.ac.jp/record/20234/files/KJ00006017724.pdf"}, "version_id": "2fe02df8-2b1f-48d7-9296-cbbda027556d"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "jpn"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "脳血管障害-研究と診療の進歩(6) : 虚血性脳血管障害急性期の血栓溶解療法と抗血栓療法", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "脳血管障害-研究と診療の進歩(6) : 虚血性脳血管障害急性期の血栓溶解療法と抗血栓療法"}]}, "item_type_id": "10001", "owner": "3", "path": ["2024"], "permalink_uri": "http://hdl.handle.net/10470/27533", "pubdate": {"attribute_name": "公開日", "attribute_value": "2010-08-10"}, "publish_date": "2010-08-10", "publish_status": "0", "recid": "20234", "relation": {}, "relation_version_is_last": true, "title": ["脳血管障害-研究と診療の進歩(6) : 虚血性脳血管障害急性期の血栓溶解療法と抗血栓療法"], "weko_shared_id": -1}
脳血管障害-研究と診療の進歩(6) : 虚血性脳血管障害急性期の血栓溶解療法と抗血栓療法
http://hdl.handle.net/10470/27533
http://hdl.handle.net/10470/27533f2add752-7ad3-4f02-8741-93de3bf6b878
名前 / ファイル | ライセンス | アクション |
---|---|---|
KJ00006017724.pdf (645.5 kB)
|
|
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2010-08-10 | |||||
タイトル | ||||||
タイトル | 脳血管障害-研究と診療の進歩(6) : 虚血性脳血管障害急性期の血栓溶解療法と抗血栓療法 | |||||
言語 | ||||||
言語 | jpn | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
別タイトル | ||||||
その他のタイトル | Cerebrovascular Disease : Recent Progress in Research and Clinical Practice (6) : Thrombolytic and Antiplatelet Therapies in Patients with Acute Ischemic Stroke | |||||
著者名 |
内山, 真一郎
× 内山, 真一郎 |
|||||
著者別名 | ||||||
姓名 | UCHIYAMA, Shinichiro | |||||
出版者 | ||||||
出版者 | 東京女子医科大学学会 | |||||
受付日付 | ||||||
日付 | 2010-08-10 | |||||
日付タイプ | Created | |||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 0040-9022 | |||||
NCID | ||||||
収録物識別子タイプ | NCID | |||||
収録物識別子 | AN00161368 | |||||
書誌情報 |
東京女子医科大学雑誌 巻 77, 号 7, p. 319-324, 発行日 2007-07 |
|||||
著者版フラグ | ||||||
出版タイプ | VoR | |||||
出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Recent evidence and present consensus as well as the future direction of thrombolytic and antithrombotic therapies for the treatment of acute ischemic stroke were reviewed. Intravenous tissue plasminogen activator (t-PA; alteplase) has recently been approved in Japan to use in patients with ischemic stroke within 3 hours of onset. In order to improve the efficacy and maximize the safety, attempts have recently been made to select patients on the basis of perfusion/diffusion mismatch on magnetic resonance imaging, use of third generation t-PAs, and concomitant use of transcranial Doppler or clot retrieval device. Neither unfractionated heparin, low molecular weight heparin, or heparinoid has been proven to improve long-term outcome, while anticoagulant therapy appears to be indicated for the treatment of patients with atherothrombotic stroke, progressing stroke, basilar artery thrombosis, cardioembolic stroke at high risk of early recurrence, coagulopathy including antiphospholipid antibody and Trousseau's syndrome, and intracranial arterial dissection. The thrombin inhibitor argatroban is recommended for the treatment of atherothrombotic stroke within 48 hours of onset. Among antiplatelet agents, aspirin is recommended in patients with ischemic stroke within 48 hours of onset, although the long-term efficacy is modest. The thromboxane synthetase inhibitor ozagrel is also recommended in the Japanese guideline. A trial of the glycoprotein IIb/IIIa inhibitor abciximab has been discontinued because of safety concerns. Many clinical trials of dual antiplatelet therapy are ongoing in patients with acute ischemic stroke. | |||||
著者所属 | ||||||
東京女子医科大学医学部神経内科学 | ||||||
著者キーワード | ||||||
主題Scheme | Other | |||||
主題 | tissue-plasminogen activator | |||||
著者キーワード | ||||||
主題Scheme | Other | |||||
主題 | anticoagulants | |||||
著者キーワード | ||||||
主題Scheme | Other | |||||
主題 | antiplatelet agents | |||||
著者キーワード | ||||||
主題Scheme | Other | |||||
主題 | acute ischemic stroke | |||||
著者キーワード | ||||||
主題Scheme | Other | |||||
主題 | guidelines |